Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury

Journal of Molecular and Cellular Cardiology

Volumn 80, Issue , 2015, Pages 10-19

  Liu, Jianxun ^a   Zhu, Hua ^b   Zheng, Yongqiu ^a   Xu, Zhaobin ^b   Li, Lei ^a   Tan, Tao ^c   Park, Ki Ho ^b   Hou, Jincai ^a   Zhang, Cuixiang ^a   Li, Dan ^a   Li, Ran ^a   Liu, Zhenguo ^b   Weisleder, Noah ^b,c   Zhu, Desheng ^d   Lin, Peihui ^b   Ma, Jianjie ^b,c  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c TRIM edicine Inc   (United States)

^d PEKING UNIVERSITY   (China)

Author keywords

Angioplasty; Cell membrane repair; Myocardial infarction; Myocardial ischemia; TRIM72

Indexed keywords

CARDIAC AGENT; CREATINE KINASE; RECOMBINANT HUMAN MG53 PROTEIN; TROPONIN I; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; CARRIER PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MITSUGUMIN 53, HUMAN; PROTEIN KINASE B; RECOMBINANT PROTEIN;

ACUTE HEART INFARCTION; ANGIOPLASTY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HEART EJECTION FRACTION; HEART INFARCTION SIZE; HEART MUSCLE FIBER MEMBRANE; HEART OUTPUT; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERVENTRICULAR SEPTAL THICKNESS; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PROTEIN SECRETION; RAT; REPERFUSION INJURY; SWINE; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HEART MUSCLE; HUMAN; IN VITRO STUDY; METABOLISM; MORTALITY; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PIG; SIGNAL TRANSDUCTION;

RODENTIA; SUS;

ANIMALS; CARDIOTONIC AGENTS; CARRIER PROTEINS; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IN VITRO TECHNIQUES; MALE; MICE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SWINE;

EID: 84920146429     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.12.010     Document Type: Article

References (37)

1. Kloner R.A. Does reperfusion injury exist in humans?. J Am Coll Cardiol 1993, 21:537-545.
2. Opie L.H. Reperfusion injury and its pharmacologic modification. Circulation 1989, 80:1049-1062.
3. Garcia-Dorado D., Ruiz-Meana M., Piper H.M. Lethal reperfusion injury in acute myocardial infarction: facts and unresolved issues. Cardiovasc Res 2009, 83:165-168.
4. Hearse D.J., Bolli R. Reperfusion-induced injury manifestations, mechanisms, and clinical relevance. Trends Cardiovasc Med 1991, 1:233-240.
5. Walters A.M., Porter G.A., Brookes P.S. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res 2012, 111:1222-1236.
6. Kramer J.H., Misik V., Weglicki W.B. Lipid peroxidation-derived free radical production and postischemic myocardial reperfusion injury. Ann N Y Acad Sci 1994, 723:180-196.
7. Hoffman J.W., Gilbert T.B., Poston R.S., Silldorff E.P. Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol 2004, 36:391-411.
8. Hausenloy D.J., Yellon D.M. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 2011, 8:619-629.
9. Hausenloy D.J., Yellon D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 2013, 123:92-100.
10. Bell R., Beeuwkes R., Botker H.E., Davidson S., Downey J., Garcia-Dorado D., et al. Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 2012, 107:300.
11. Hausenloy D.J., Baxter G., Bell R., Botker H.E., Davidson S.M., Downey J., et al. Translating novel strategies for cardioprotection: the Hatter Workshop recommendations. Basic Res Cardiol 2010, 105:677-686.
12. Schwartz Longacre L., Kloner R.A., Arai A.E., Baines C.P., Bolli R., Braunwald E., et al. New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation 2011, 124:1172-1179.
13. Hausenloy D.J., Erik Botker H., Condorelli G., Ferdinandy P., Garcia-Dorado D., Heusch G., et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2013, 98:7-27.
14. Tam S.K., Gu W., Mahdavi V., Nadal-Ginard B. Cardiac myocyte terminal differentiation. Potential for cardiac regeneration. Ann N Y Acad Sci 1995, 752:72-79.
15. Clarke M.S., Caldwell R.W., Chiao H., Miyake K., McNeil P.L. Contraction-induced cell wounding and release of fibroblast growth factor in heart. Circ Res 1995, 76:927-934.
16. Cai C., Masumiya H., Weisleder N., Matsuda N., Nishi M., Hwang M., et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 2009, 11:56-64.
17. Lin P., Zhu H., Cai C., Wang X., Cao C., Xiao R., et al. Nonmuscle myosin IIA facilitates vesicle trafficking for MG53-mediated cell membrane repair. FASEB J 2012, 26:1875-1883.
18. Zhu H., Lin P., De G., Choi K.H., Takeshima H., Weisleder N., et al. Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J Biol Chem 2011, 286:12820-12824.
19. Wang X., Xie W., Zhang Y., Lin P., Han L., Han P., et al. Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res 2010, 107:76-83.
20. Cao C.M., Zhang Y., Weisleder N., Ferrante C., Wang X., Lv F., et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 2010, 121:2565-2574.
21. He B., Tang R.H., Weisleder N., Xiao B., Yuan Z., Cai C., et al. Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in delta-sarcoglycan-deficient hamsters. Mol Ther 2012, 20:727-735.
22. Weisleder N., Takizawa N., Lin P., Wang X., Cao C., Zhang Y., et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 2012, 4:139ra85.
23. Jia Y., Chen K., Lin P., Lieber G., Nishi M., Yan R., et al. Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nat Commun 2014, 5:4387.
24. Xiao C.Y., Hara A., Yuhki K., Fujino T., Ma H., Okada Y., et al. Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 2001, 104:2210-2215.
25. Karlsson L.O., Bergh N., Li L., Bissessar E., Bobrova I., Gross G.J., et al. Dose-dependent cardioprotection of enkephalin analogue Eribis peptide 94 and cardiac expression of opioid receptors in a porcine model of ischaemia and reperfusion. Eur J Pharmacol 2012, 674:378-383.
26. Andreka G., Vertesaljai M., Szantho G., Font G., Piroth Z., Fontos G., et al. Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart 2007, 93:749-752.
27. Parisi A.F., Moynihan P.F., Feldman C.L., Folland E.D. Approaches to determination of left ventricular volume and ejection fraction by real-time two-dimensional echocardiography. Clin Cardiol 1979, 2:257-263.
28. Huang S., Patterson E., Yu X., Garrett M.W., De Aos I., Kem D.C. Proteasome inhibition 1h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol 2008, 294:H1298-H1303.
29. Suzuki Y., Yeung A.C., Ikeno F. The pre-clinical animal model in the translational research of interventional cardiology. JACC Cardiovasc Interv 2009, 2:373-383.
30. Schwartz R.S., Edelman E.R., Carter A., Chronos N.A., Rogers C., Robinson K.A., et al. Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation 2004, 110:2498-2505.
31. Cummins B., Auckland M.L., Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987, 113:1333-1344.
32. Cai C., Masumiya H., Weisleder N., Pan Z., Nishi M., Komazaki S., et al. MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem 2009, 284:3314-3322.
33. Kohr M.J., Evangelista A.M., Ferlito M., Steenbergen C., Murphy E. S-nitrosylation of TRIM72 at cysteine 144 is critical for protection against oxidation-induced protein degradation and cell death. J Mol Cell Cardiol 2014, 69:67-74.
34. Zhang Y., Lv F., Jin L., Peng W., Song R., Ma J., et al. MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovasc Res 2011, 91:108-115.
35. Yi J.S., Park J.S., Ham Y.M., Nguyen N., Lee N.R., Hong J., et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun 2013, 4:2354.
36. Song R., Peng W., Zhang Y., Lv F., Wu H.K., Guo J., et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 2013, 494:375-379.
37. Nguyen N., Yi J.S., Park H., Lee J.S., Ko Y.G. Mitsugumin 53 (MG53) ligase ubiquitinates focal adhesion kinase during skeletal myogenesis. J Biol Chem 2014, 289:3209-3216.